Address correspondence to: Zelma C. Chiesa-Fuxench, Department of Dermatology,
University of Puerto Rico School of Medicine, PO Box 365067 San Juan, Puerto Rico 00936 …

Extracorporeal photopheresis (ECP) is an apheresis procedure that is conventionally used
as a first-line treatment for cutaneous and leukemic subtypes of T-cell lymphoma, such as …

Introduction: Extracorporeal photopheresis (ECP) has been extensively used for the
treatment of immune-mediated diseases for over 20 years and has a consistent and …

Extracorporeal photopheresis (ECP) is a well‐tolerated procedure that suppresses T‐
lymphocyte activity in a clonally‐specific way. It is an effective therapy that has established …

The clinical use of extracorporeal photopheresis (ECP) for accepted indications such as
graft-versus-host disease, transplant rejection, and cutaneous T-cell lymphoma continues to …

Extracorporeal photochemotherapy (ECP) is considered as an immune modulating therapy
majorly targeting the T cells of the Immune system. ECP induces an anti-inflammatory …

Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …

Extracorporeal photopheresis (ECP) is a technique that was developed> 20 years ago to
treat erythrodermic cutaneous T‐cell lymphoma (CTCL). The technique involves removal of …

Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

Extracorporeal photopheresis (ECP) is the first FDA approved cellular photoimmunotherapy
for cancer, namely cutaneous T-cell lymphoma, and has demonstrated efficacy in various …